慢性肝疾患治療薬の世界市場レポート 2025年

慢性肝疾患治療薬の市場規模は今後数年で急成長が見込まれます。2029年の年間平均成長率（CAGR）は10.6%で、238億3,000万米ドルに成長します。予測期間における成長の背景には、個別化医療への注目の高まり、新規治療薬のパイプラインの急増、遠隔医療とデジタルヘルスソリューションの拡大、肝疾患予防プログラムに対する需要の高まり、ウイルス性肝炎の罹患率の増加などがあります。主な動向としては、診断における人工知能の統合、生物製剤と遺伝子治療の開発、非侵襲的治療オプションの出現、併用療法の採用、患者中心のケアモデルの拡大などが挙げられます。

アルコールの消費量の増加は、慢性肝疾患治療薬市場の成長を促進すると予想されます。アルコール消費とは、健康に影響を与える可能性のある中程度から過剰な使用まで、エタノールを含む飲料の摂取を指します。アルコール消費の増加は、社会的受容の拡大、所得の増加、世界の入手のしやすさなどに起因しています。慢性肝疾患治療薬は、アルコールの過剰摂取によって引き起こされる肝障害を管理し、疾患の進行を遅らせ、肝機能を高める上で重要な役割を果たしています。例えば、2024年6月、米国の金融機関であるファースト・シチズンズ銀行は、2023年のDTC（Direct-to-Consumer）ワインケースの売上が2022年比で1.2％増加したと報告しました。さらに、2023年12月、日本の飲料会社であるキリンホールディングス株式会社が発表した報告書によると、2022年のビールの消費量は約1億9,210万キロリットルで、前年比2.9%増となりました。その結果、アルコール消費量の増加が慢性肝疾患治療薬市場の拡大に寄与しています。

慢性肝疾患治療薬分野の主要企業は、遺伝的・分子的メカニズムに対処し、より的を絞った効果的な治療選択肢を提供するため、RNA療法などの先進的イノベーションの開発を優先しています。RNA療法は、遺伝子発現やタンパク質産生を制御するためにRNA分子を利用する最先端の医療であり、特定の遺伝的メカニズムを標的とすることで疾患の治療や予防を目指します。例えば、2022年5月、英国のバイオテクノロジー企業Ochre Bio社は、ニューヨークのバイオファーマ・インキュベーターBioLabs@NYULangoneに「肝臓ICU」調査施設を導入しました。この先進的な施設では、灌流装置で管理された全ヒト肝臓を用いて、次世代RNA治療薬の有効性を評価します。廃棄されるドナーの肝臓を研究に利用することで、この施設は医薬品開発を加速し、ヒトの生理学的条件を再現することで肝臓治療研究の精度を高めようとしています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界慢性肝疾患治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の慢性肝疾患治療薬市場：成長率分析
• 世界の慢性肝疾患治療薬市場の実績：規模と成長, 2019-2024
• 世界の慢性肝疾患治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界慢性肝疾患治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の慢性肝疾患治療薬市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗ウイルス薬
• 免疫抑制剤ワクチン
• 免疫グロブリン
• コルチコステロイド
• 標的療法
• 化学療法
• 世界の慢性肝疾患治療薬市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 肝炎
• 自己免疫疾患
• 非アルコール性脂肪性肝疾患
• がん
• 遺伝性疾患
• 世界の慢性肝疾患治療薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の慢性肝疾患治療薬市場抗ウイルス薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヌクレオシドまたはヌクレオチド類似体
• インターフェロン
• 直接作用型抗ウイルス薬
• 世界の慢性肝疾患治療薬市場免疫抑制剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• カルシニューリン阻害剤
• mTOR阻害剤
• プリン合成阻害剤
• 世界の慢性肝疾患治療薬市場、ワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• A型肝炎ワクチン
• B型肝炎ワクチン
• 混合肝炎ワクチン
• 世界の慢性肝疾患治療薬市場免疫グロブリンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• B型肝炎免疫グロブリン
• 静脈内免疫グロブリン
• 世界の慢性肝疾患治療薬市場コルチコステロイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プレドニゾロン
• メチルプレドニゾロン
• デキサメタゾン
• 世界の慢性肝疾患治療薬市場標的療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• チロシンキナーゼ阻害剤
• モノクローナル抗体
• 世界の慢性肝疾患治療薬市場化学療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 全身化学療法
• 動脈塞栓化学療法剤

第7章 地域別・国別分析

• 世界の慢性肝疾患治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の慢性肝疾患治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 慢性肝疾患治療薬市場：競合情勢
• 慢性肝疾患治療薬市場：企業プロファイル
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Gilead Sciences Inc.
• Novo Nordisk A/S
• Dr. Reddy's Laboratories Ltd.
• Vir Biotechnology Inc.
• Alnylam Pharmaceuticals Inc.
• Indian Immunologicals Limited
• Intercept Pharmaceuticals Inc.
• Viking Therapeutics Inc.
• Ascletis Pharma Inc.
• Ochre Bio Limited
• Tiziana Life Sciences Ltd.
• Antios Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 慢性肝疾患治療薬市場2029：新たな機会を提供する国
• 慢性肝疾患治療薬市場2029：新たな機会を提供するセグメント
• 慢性肝疾患治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Chronic liver disease therapeutics encompasses the treatments and interventions designed to manage long-term liver conditions. These therapies aim to slow disease progression, alleviate symptoms, and enhance liver function through the use of medications, lifestyle modifications, and, in some cases, advanced procedures.

The primary treatment types in chronic liver disease therapeutics include antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapies, and chemotherapy. Antiviral drugs are specifically formulated to inhibit the replication of viruses in the body, aiding in the treatment and management of viral infections. These therapies address a range of conditions such as hepatitis, autoimmune diseases, non-alcoholic fatty liver disease, cancer, and genetic disorders. Distribution channels for these treatments include hospital pharmacies, retail pharmacies, and online pharmacies.

The chronic liver diseases therapeutics market research report is one of a series of new reports from The Business Research Company that provides chronic liver diseases therapeutics market statistics, including the chronic liver diseases therapeutics industry global market size, regional shares, competitors with the chronic liver diseases therapeutics market share, detailed chronic liver diseases therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic liver diseases therapeutics industry. This chronic liver diseases therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chronic liver disease therapeutics market size has grown rapidly in recent years. It will grow from $14.38 billion in 2024 to $15.92 billion in 2025 at a compound annual growth rate (CAGR) of 10.7%. The growth observed during the historical period can be attributed to a rise in the incidence of viral hepatitis, increasing obesity rates, an aging population, enhanced awareness of liver health, and improved patient access to treatment.

The chronic liver disease therapeutics market size is expected to see rapid growth in the next few years. It will grow to $23.83 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The projected growth in the forecast period can be attributed to an increased focus on personalized medicine, a burgeoning pipeline of novel therapies, the expansion of telemedicine and digital health solutions, a rising demand for liver disease prevention programs, and the increasing incidence of viral hepatitis. Major trends include the integration of artificial intelligence in diagnostics, the development of biologics and gene therapies, the emergence of non-invasive treatment options, the adoption of combination therapies, and the expansion of patient-centric care models.

The rising consumption of alcohol is expected to drive the growth of the chronic liver disease therapeutics market. Alcohol consumption refers to the intake of ethanol-containing beverages, ranging from moderate to excessive use, which can impact health. The increase in alcohol consumption is attributed to growing social acceptance, higher incomes, and greater accessibility worldwide. Chronic liver disease therapeutics play a crucial role in managing liver damage caused by excessive alcohol intake, slowing disease progression, and enhancing liver function. For example, in June 2024, First Citizens Bank, a US financial institution, reported a 1.2% rise in direct-to-consumer (DTC) wine case sales in 2023 compared to 2022. Additionally, in December 2023, a report published by Kirin Holdings Company Limited, a Japan-based beverage company, indicated that approximately 192.1 million kiloliters of beer were consumed in 2022, marking a 2.9% increase from the previous year. As a result, the rising consumption of alcohol is contributing to the expansion of the chronic liver disease therapeutics market.

Leading companies in the chronic liver disease therapeutics sector are prioritizing the development of advanced innovations, such as RNA therapies, to address genetic and molecular mechanisms, providing more targeted and effective treatment options. RNA therapies are cutting-edge medical treatments that utilize RNA molecules to regulate gene expression or protein production, with the aim of treating or preventing diseases by targeting specific genetic mechanisms. For instance, in May 2022, Ochre Bio, a UK-based biotech company, introduced its 'Liver ICU' research facility at BioLabs@NYULangone, a biopharma incubator in New York City. This advanced facility evaluates the efficacy of next-generation RNA therapeutics using whole human livers maintained on perfusion machines. By utilizing discarded donor livers for research, the facility seeks to accelerate drug development and enhance the accuracy of liver treatment studies by replicating human physiological conditions.

In March 2024, Gilead Sciences Inc., a US-based pharmaceutical company, completed the acquisition of CymaBay Therapeutics Inc. for approximately $4.3 billion. This acquisition is intended to strengthen Gilead Sciences' portfolio in liver disease treatments, with a particular emphasis on non-alcoholic steatohepatitis (NASH) and other chronic liver conditions. CymaBay Therapeutics Inc. is a US-based company dedicated to developing therapies for liver diseases, including chronic liver conditions.

Major players in the chronic liver diseases therapeutics market are F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Novo Nordisk A/S, Dr. Reddy's Laboratories Ltd., Vir Biotechnology Inc., Alnylam Pharmaceuticals Inc., Indian Immunologicals Limited, Intercept Pharmaceuticals Inc., Viking Therapeutics Inc., Ascletis Pharma Inc., Ochre Bio Limited, Tiziana Life Sciences Ltd., Antios Therapeutics Inc.

North America was the largest region in the chronic liver diseases therapeutics market in 2024. The regions covered in chronic liver diseases therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chronic liver diseases therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic liver disease therapeutics market includes revenues earned by entities by providing services such as genetic and molecular testing, liver transplantation, enzyme inhibitors, regular monitoring, and palliative and symptomatic care and related products, including pharmacological treatments, drugs, and emerging therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Liver Diseases Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic liver diseases therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chronic liver diseases therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chronic liver diseases therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Antiviral Drugs; Immunosuppressants Vaccines; Immunoglobulins; Corticosteroids; Targeted Therapy; Chemotherapy
• 2) By Disease Type: Hepatitis; Autoimmune Diseases; Non-Alcoholic Fatty Liver Disease; Cancer; Genetic Disorders
• 3) By Application: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Antiviral Drugs: Nucleoside Or Nucleotide Analogues; Interferons; Direct-Acting Antivirals
• 2) By Immunosuppressants: Calcineurin Inhibitors; mTOR Inhibitors; Purine Synthesis Inhibitors
• 3) By Vaccines: Hepatitis A Vaccine; Hepatitis B Vaccine; Combination Hepatitis Vaccines
• 4) By Immunoglobulins: Hepatitis B Immune Globulin; Intravenous Immunoglobulin
• 5) By Corticosteroids: Prednisolone; Methylprednisolone; Dexamethasone
• 6) By Targeted Therapy: Tyrosine Kinase Inhibitors; Monoclonal Antibodies
• 7) By Chemotherapy: Systemic Chemotherapy; Transarterial Chemoembolization Agents
• Companies Mentioned: F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Bristol-Myers Squibb Company; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Chronic Liver Diseases Therapeutics Market Characteristics

3. Chronic Liver Diseases Therapeutics Market Trends And Strategies

4. Chronic Liver Diseases Therapeutics Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Chronic Liver Diseases Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Chronic Liver Diseases Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Chronic Liver Diseases Therapeutics Market Growth Rate Analysis
• 5.4. Global Chronic Liver Diseases Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Chronic Liver Diseases Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Chronic Liver Diseases Therapeutics Total Addressable Market (TAM)

6. Chronic Liver Diseases Therapeutics Market Segmentation

• 6.1. Global Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiviral Drugs
• Immunosuppressants Vaccines
• Immunoglobulins
• Corticosteroids
• Targeted Therepy
• Chemotherapy
• 6.2. Global Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hepatitis
• Autoimmune Diseases
• Non-Alcoholic Fatty Liver Disease
• Cancer
• Genetic Disorders
• 6.3. Global Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Chronic Liver Diseases Therapeutics Market, Sub-Segmentation Of Antiviral Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nucleoside Or Nucleotide Analogues
• Interferons
• Direct-Acting Antivirals
• 6.5. Global Chronic Liver Diseases Therapeutics Market, Sub-Segmentation Of Immunosuppressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Calcineurin Inhibitors
• mTOR Inhibitors
• Purine Synthesis Inhibitors
• 6.6. Global Chronic Liver Diseases Therapeutics Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hepatitis A Vaccine
• Hepatitis B Vaccine
• Combination Hepatitis Vaccines
• 6.7. Global Chronic Liver Diseases Therapeutics Market, Sub-Segmentation Of Immunoglobulins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hepatitis B Immune Globulin
• Intravenous Immunoglobulin
• 6.8. Global Chronic Liver Diseases Therapeutics Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prednisolone
• Methylprednisolone
• Dexamethasone
• 6.9. Global Chronic Liver Diseases Therapeutics Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tyrosine Kinase Inhibitors
• Monoclonal Antibodies
• 6.10. Global Chronic Liver Diseases Therapeutics Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Systemic Chemotherapy
• Transarterial Chemoembolization Agents

7. Chronic Liver Diseases Therapeutics Market Regional And Country Analysis

• 7.1. Global Chronic Liver Diseases Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Chronic Liver Diseases Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chronic Liver Diseases Therapeutics Market

• 8.1. Asia-Pacific Chronic Liver Diseases Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chronic Liver Diseases Therapeutics Market

• 9.1. China Chronic Liver Diseases Therapeutics Market Overview
• 9.2. China Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chronic Liver Diseases Therapeutics Market

• 10.1. India Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chronic Liver Diseases Therapeutics Market

• 11.1. Japan Chronic Liver Diseases Therapeutics Market Overview
• 11.2. Japan Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chronic Liver Diseases Therapeutics Market

• 12.1. Australia Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chronic Liver Diseases Therapeutics Market

• 13.1. Indonesia Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chronic Liver Diseases Therapeutics Market

• 14.1. South Korea Chronic Liver Diseases Therapeutics Market Overview
• 14.2. South Korea Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chronic Liver Diseases Therapeutics Market

• 15.1. Western Europe Chronic Liver Diseases Therapeutics Market Overview
• 15.2. Western Europe Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chronic Liver Diseases Therapeutics Market

• 16.1. UK Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chronic Liver Diseases Therapeutics Market

• 17.1. Germany Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chronic Liver Diseases Therapeutics Market

• 18.1. France Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chronic Liver Diseases Therapeutics Market

• 19.1. Italy Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chronic Liver Diseases Therapeutics Market

• 20.1. Spain Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chronic Liver Diseases Therapeutics Market

• 21.1. Eastern Europe Chronic Liver Diseases Therapeutics Market Overview
• 21.2. Eastern Europe Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chronic Liver Diseases Therapeutics Market

• 22.1. Russia Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chronic Liver Diseases Therapeutics Market

• 23.1. North America Chronic Liver Diseases Therapeutics Market Overview
• 23.2. North America Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chronic Liver Diseases Therapeutics Market

• 24.1. USA Chronic Liver Diseases Therapeutics Market Overview
• 24.2. USA Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chronic Liver Diseases Therapeutics Market

• 25.1. Canada Chronic Liver Diseases Therapeutics Market Overview
• 25.2. Canada Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chronic Liver Diseases Therapeutics Market

• 26.1. South America Chronic Liver Diseases Therapeutics Market Overview
• 26.2. South America Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chronic Liver Diseases Therapeutics Market

• 27.1. Brazil Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chronic Liver Diseases Therapeutics Market

• 28.1. Middle East Chronic Liver Diseases Therapeutics Market Overview
• 28.2. Middle East Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chronic Liver Diseases Therapeutics Market

• 29.1. Africa Chronic Liver Diseases Therapeutics Market Overview
• 29.2. Africa Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chronic Liver Diseases Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Chronic Liver Diseases Therapeutics Market Competitive Landscape
• 30.2. Chronic Liver Diseases Therapeutics Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Chronic Liver Diseases Therapeutics Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. Eli Lilly and Company
• 31.4. Gilead Sciences Inc.
• 31.5. Novo Nordisk A/S
• 31.6. Dr. Reddy's Laboratories Ltd.
• 31.7. Vir Biotechnology Inc.
• 31.8. Alnylam Pharmaceuticals Inc.
• 31.9. Indian Immunologicals Limited
• 31.10. Intercept Pharmaceuticals Inc.
• 31.11. Viking Therapeutics Inc.
• 31.12. Ascletis Pharma Inc.
• 31.13. Ochre Bio Limited
• 31.14. Tiziana Life Sciences Ltd.
• 31.15. Antios Therapeutics Inc.

32. Global Chronic Liver Diseases Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chronic Liver Diseases Therapeutics Market

34. Recent Developments In The Chronic Liver Diseases Therapeutics Market

35. Chronic Liver Diseases Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Chronic Liver Diseases Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Chronic Liver Diseases Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Chronic Liver Diseases Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer